Allergan Declines To Confirm Abicipar Pegol Fate
Is There A Future For The Investigational Ophthalmic Treatment?
Executive Summary
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
You may also be interested in...
US FDA Picks Up The Pace Of Complete Response Letters Over June And July
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
Allergan Pulls EU Filing For Abicipar Pegol
The withdrawal of the EU filing for abicipar pegol will fuel speculation that Allergan parent AbbVie is indeed ditching the potential treatment for wet AMD. US regulators have already said they won't approve the drug.
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.